[go: up one dir, main page]

BR9908857A - Métodos e composições para tratamento, inibição e prevenção de mucosite - Google Patents

Métodos e composições para tratamento, inibição e prevenção de mucosite

Info

Publication number
BR9908857A
BR9908857A BR9908857-6A BR9908857A BR9908857A BR 9908857 A BR9908857 A BR 9908857A BR 9908857 A BR9908857 A BR 9908857A BR 9908857 A BR9908857 A BR 9908857A
Authority
BR
Brazil
Prior art keywords
compositions
treating
methods
inhibiting
preventing mucositis
Prior art date
Application number
BR9908857-6A
Other languages
English (en)
Inventor
Stephen T Sonis
Edward G Fey
Original Assignee
Mucosal Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mucosal Therapeutics Llc filed Critical Mucosal Therapeutics Llc
Publication of BR9908857A publication Critical patent/BR9908857A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<B>''MéTODOS E COMPOSIçõES PARA TRATAMENTO E PREVENçãO DE MUCOSITE'' <D> Um método de redução ou inibição mucosite em um paciente, o qual compreende administração de um inibidor de citoquina inflamatória ou um inibidor de célula tronco ou uma combinação deles, é revelado.
BR9908857-6A 1998-03-13 1999-03-12 Métodos e composições para tratamento, inibição e prevenção de mucosite BR9908857A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7797798P 1998-03-13 1998-03-13
US6501298A 1998-04-23 1998-04-23
US09/265,299 US6458777B1 (en) 1998-03-13 1999-03-09 Methods and compositions for treating and preventing mucositis
PCT/US1999/005437 WO1999045910A2 (en) 1998-03-13 1999-03-12 Methods and compositions for treating and preventing mucositis

Publications (1)

Publication Number Publication Date
BR9908857A true BR9908857A (pt) 2000-10-31

Family

ID=27370718

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9908857-6A BR9908857A (pt) 1998-03-13 1999-03-12 Métodos e composições para tratamento, inibição e prevenção de mucosite

Country Status (12)

Country Link
US (3) US6458777B1 (pt)
EP (1) EP1064001A2 (pt)
JP (2) JP2002506023A (pt)
AU (1) AU753288B2 (pt)
BR (1) BR9908857A (pt)
CA (1) CA2323863C (pt)
DE (1) DE1064001T1 (pt)
GR (1) GR20010300060T1 (pt)
IL (1) IL138430A0 (pt)
NZ (1) NZ506931A (pt)
PL (1) PL343442A1 (pt)
WO (1) WO1999045910A2 (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0987552A3 (en) 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6946118B1 (en) * 1999-09-14 2005-09-20 Orapharma, Inc. Formulations for treating or preventing mucositis
PT1212050E (pt) * 1999-09-14 2007-03-30 Mucosal Therapeutics Llc Formulações contendo tetraciclinas para tratar ou evitar a mucosite
EP1267826B1 (en) * 1999-10-22 2007-01-03 Lif-Hlaup Ehf. Bio-Gels Pharmaceuticals Inc. Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion
US6677321B1 (en) * 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
US20010025027A1 (en) * 2000-03-07 2001-09-27 Sonis Stephen T. Inhibition of ceramide for the prevention and treatment of oral mucositis induced by antineoplastic drugs or radiation
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US8980334B2 (en) * 2001-02-28 2015-03-17 Axiomedic Ltd. Double-layered absorbable solid compositions for the topical treatment of oral mucosal disorders
EP2324821A1 (en) * 2001-02-28 2011-05-25 Axiomedic Ltd. Oral care compositions
WO2003024391A2 (en) * 2001-08-16 2003-03-27 Mucosal Therapeutics, Inc. Treatment and prevention of mucositis in cancer patients
US20030059378A1 (en) * 2001-09-06 2003-03-27 Libin Barry M. Method of preventing mucositis
US20040029843A1 (en) * 2002-06-20 2004-02-12 Orapharma, Inc. Rapidly disintegrating formulations for treating or preventing mucositis
US20040254152A1 (en) * 2003-04-17 2004-12-16 Monje Michelle L. Prevention of deficits in neurogenesis with anti-inflammatory agents
GB0326393D0 (en) * 2003-11-12 2003-12-17 Ares Trading Sa Cytokine antagonist molecules
US7914831B2 (en) * 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
EP1838288A4 (en) * 2004-12-20 2010-08-04 Ariad Pharma Inc THERAPEUTIC MATERIALS AND METHODS
DK1704860T3 (da) * 2005-03-24 2011-02-07 Rottapharm Spa Benzamidinderivater til behandling og forebyggelse af mucositis
US8568333B2 (en) * 2006-05-01 2013-10-29 Devicor Medical Products, Inc. Grid and rotatable cube guide localization fixture for biopsy device
US20070281927A1 (en) * 2006-06-06 2007-12-06 Shanthakumar Tyavanagimatt Anti-inflammatory and analgesic compositions and related methods
BRPI0722054A2 (pt) * 2006-12-28 2014-04-01 Limerick Biopharma Inc Composição, kit, e métodos para diminuir um efeito colateral de tratamento com um inibidor da calcineurina, para aumentar um efeito terapêutico de um inibidor da calcineurina e para mudar a concentração de tacrolimus ou um análogo de tacrolimus em um compartimento fisiológico.
AU2008282261A1 (en) * 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Phosphorylated pyrone analogs and methods
US9161909B2 (en) * 2007-08-24 2015-10-20 Axiomedic Ltd. Adhesive compositions for the treatment of xerostomia
CA2734139C (en) * 2007-10-02 2019-12-24 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
WO2009158031A2 (en) * 2008-06-27 2009-12-30 Limerick Biopharma, Inc. Methods and compositions for therapeutic treatment
US9549842B2 (en) 2011-02-04 2017-01-24 Joseph E. Kovarik Buccal bioadhesive strip and method of treating snoring and sleep apnea
US8701671B2 (en) 2011-02-04 2014-04-22 Joseph E. Kovarik Non-surgical method and system for reducing snoring
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
SI2794626T1 (en) 2011-12-22 2018-02-28 Glycomimetics, Inc. E-SELECTINE ANTAGONIST COMPOUNDS
SI2928476T1 (en) 2012-12-07 2018-06-29 Glycomimetics, Inc. COMPONENTS, INSTALLATIONS AND PROCEDURES OF THE APPLICATION OF E-SELECTINE OF ANTAGONISTS FOR THE MOBILIZATION OF HEMATOPOETIC CELLS
CN105683208A (zh) * 2013-09-30 2016-06-15 糖模拟物有限公司 治疗和/或预防粘膜炎的方法和组合物
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
DK3227310T3 (da) 2014-12-03 2019-09-30 Glycomimetics Inc Heterobifunktionelle inhibitorer af e-selektiner og cxcr4-kemokin-receptorer
US10610588B2 (en) 2015-02-09 2020-04-07 Yeda Research And Development Co. Ltd. Methods of preventing secondary infections
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
US11433086B2 (en) 2016-08-08 2022-09-06 Glycomimetics, Inc. Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
CN117298287A (zh) 2016-10-07 2023-12-29 糖模拟物有限公司 高效的多聚体e-选择蛋白拮抗剂
JP7272956B2 (ja) 2017-03-15 2023-05-12 グリコミメティクス， インコーポレイテッド Ｅ－セレクチンアンタゴニストとしてのガラクトピラノシル－シクロヘキシル誘導体
US11712446B2 (en) 2017-11-30 2023-08-01 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
KR20200104889A (ko) 2017-12-29 2020-09-04 글리코미메틱스, 인크. E-셀렉틴 및 갈렉틴-3의 이종이기능성 억제제
CN111867601A (zh) 2018-03-05 2020-10-30 糖模拟物有限公司 用于治疗急性髓系白血病及相关病症的方法
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
CA3257661A1 (en) * 2022-05-31 2023-12-07 Vivasor, Inc. METHOD FOR TREATING AN INFLAMMATORY DYSFUNCTION OF THE ORAL MUCOSA

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666897A (en) 1983-12-29 1987-05-19 Research Foundation Of State University Inhibition of mammalian collagenolytic enzymes by tetracyclines
US5190917A (en) 1986-12-24 1993-03-02 John Lezdey Treatment of psoriasis
WO1990001950A1 (en) 1988-08-19 1990-03-08 Celltech Limited Pharmaceutical products for anti-neoplastic therapy
US5674708A (en) 1989-06-23 1997-10-07 Trustees Of The University Of Pennsylvania α-1-antichymotrypsin analogues having elastase inhibitory activity
US5192780A (en) 1989-12-18 1993-03-09 Alcon Laboratories, Inc. Methods using antiallergics and antihistamines
US5230895A (en) 1990-05-01 1993-07-27 Copley Pharmaceutical Inc. Sustained released delivery system for use in the periodontal pocket
US5824297A (en) 1990-06-25 1998-10-20 Oncogene Science, Inc. Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
US5215965A (en) 1990-10-02 1993-06-01 John Lezdey Treatment of inflammation
WO1992015286A1 (en) 1991-02-27 1992-09-17 Nova Pharmaceutical Corporation Anti-infective and anti-inflammatory releasing systems for medical devices
JPH06506198A (ja) 1991-03-04 1994-07-14 ワーナー−ランバート・コンパニー 種々な剤形の非ステロイド性抗炎症剤の新規な塩／イオン対
US5310545A (en) 1991-04-11 1994-05-10 Drore Eisen Method of treatment using mouthwashes containing steroids and antifungal agents and compositions of matter
JPH0769851A (ja) 1993-09-03 1995-03-14 Lion Corp 口腔用組成物
US5578315A (en) 1993-12-01 1996-11-26 Rutgers, The State University Of New Jersey Mucosal adhesive device for long-acting delivery of pharmaceutical combinations in oral cavity
US5434170A (en) 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
JPH08168854A (ja) * 1994-12-16 1996-07-02 Nippon Steel Corp ストッパー制御方法
JPH08268854A (ja) 1995-03-31 1996-10-15 Sunstar Inc 口腔用組成物
US5654312A (en) 1995-06-07 1997-08-05 Andrulis Pharmaceuticals Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
US5788982A (en) 1995-06-16 1998-08-04 Nadoolman; Wolffe Method and composition for treating oral pain using capsaicin
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5707653A (en) * 1995-11-17 1998-01-13 Goldberg; Arthur H. Ulcer treating composition comprising sufalcrate and antibiotic
US5846525A (en) 1995-12-19 1998-12-08 Trega Biosciences, Inc. Protected biopolymers for oral administration and methods of using same
US7189703B2 (en) * 1998-01-09 2007-03-13 Intracell, Llc Treatment and diagnosis of alzheimer's disease
US5981499A (en) * 1998-02-20 1999-11-09 Atlantic Biomed Corporation Lesion-directed antibiotics in dry dosage forms for the treatment of shallow ulcers of the oral mucosa
US6239119B1 (en) 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds

Also Published As

Publication number Publication date
AU753288B2 (en) 2002-10-17
NZ506931A (en) 2005-01-28
JP2002506023A (ja) 2002-02-26
US20010011097A1 (en) 2001-08-02
US6458777B1 (en) 2002-10-01
JP2006206613A (ja) 2006-08-10
US20030036560A1 (en) 2003-02-20
PL343442A1 (en) 2001-08-13
WO1999045910A2 (en) 1999-09-16
WO1999045910A3 (en) 2000-02-10
AU3083799A (en) 1999-09-27
EP1064001A2 (en) 2001-01-03
CA2323863A1 (en) 1999-09-16
GR20010300060T1 (en) 2001-11-30
CA2323863C (en) 2005-09-13
US6713463B2 (en) 2004-03-30
DE1064001T1 (de) 2001-12-20
IL138430A0 (en) 2001-10-31

Similar Documents

Publication Publication Date Title
BR9908857A (pt) Métodos e composições para tratamento, inibição e prevenção de mucosite
BR0111196A (pt) Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus
BR9811099A (pt) Inibidores de urocinase
DK0675714T3 (da) Kombination af en cholesterol-biosynteseinhibitor og en beta-lactam-cholesterolabsorptionsinhibitor
PL346344A1 (en) Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
PT1039912E (pt) Agentes angiostaticos e composicoes para tratar glaucoma glc1a
BR0211274A (pt) Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase
BR0311375A (pt) Composição farmacêutica, uso da mesma, e, método para o tratamento de demência ou dano cognitivo suave em um mamìfero
EP1126841A4 (en) METHODS FOR TREATING MIGRAINE AND RELATED PHARMACEUTICAL PREPARATIONS
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
PT935465E (pt) Compostos novos de imidazole substituido
PL327735A1 (en) Novel substituted derivatives of imidazole
TR199801679T2 (xx) Osteoporoz i�in birle�tirme terapisi.
PT885098E (pt) Agente de proteccao da madeira para trabalhos de manutencao
ES2196190T3 (es) Inhibidores de metaloproteinasas matriciales, con hidroxamato bifenlico.
ES2184111T3 (es) Composiciones para el tratamiento de neuropatias perifericas que contienen antidepresivos y/o inhibidores de la monoaminoxidasa y/o vitamina b12 y/o precursores o inductores de un neurotransmisor.
BR0214810A (pt) Combinação de um inibidor de il-1/18 com um inibidor de tnf para o tratamento de inflamação
DK1427409T3 (da) Fremgangsmåde til behandling eller forhindring af vaskulær inflammation under brug af en eller flere sterolabssorptionsinhibitorer
BR0110506A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
PT1039894E (pt) Composicoes para o aumento da concentracao e/ou da mobilidade dos espermatozoides em humanos
ZA991744B (en) Combination of a selective NMDA NR2B antagonist and COX-2 inhibitor.
SE9603725D0 (sv) New teatment
BR9916255A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos de tratamento de uma condição em que se requer inibição de trombina e para a preparação de compostos
ID18382A (id) Komposisi sediaan farmasi dan metoda pengobatan gangguan kompulsif dengan menggunakan inhibitor naaladase

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/65 (2008.01), A61K 45/06 (2008.01), A61P 1

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE ACORDO COM ART. 8O, 13 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.